FDA approves pralsetinib for lung cancer with RET gene fusions
The Food and Drug Administration granted accelerated approval to pralsetinib for adult patients with metastatic…
Browsing: pralsetinib
ASCO 2020: Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients…